AP
SUPN icon

AHL Partners’s Supernus Pharmaceuticals SUPN Stock Holding History

AHL Partners’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		$1.09M Sell
27,437
-90,703
-77% -$3.58M 0.02% 865
2017
Q3 		$4.73M Buy
118,140
+49,385
+72% +$2.14M 0.08% 418
2017
Q2 		$2.96M Buy
+68,755
New +$2.45M 0.06% 524

Other funds holding SUPN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
CIP
Champlain Investment Partners Burlington, Vermont $7.88B AUM 6.82% 1-Year Est. Return
RCAMU
Rothschild & Co Asset Management US Stamford, Connecticut $6.58B AUM 4.5% 1-Year Est. Return

AHL Partners's SUPN Position: Q4 2017 in Review

AHL Partners reduced its Supernus Pharmaceuticals (SUPN) stake by 77% in Q4 2017, selling an estimated $3.58M and leaving 27,437 shares worth $1.09M. The position accounts for 0.02% of the portfolio, ranked #865.

AHL Partners first reported a position in SUPN in Q2 2017 and has held it in 3 quarters since. The position peaked at $4.73M in Q3 2017. 297 funds tracked by Wall St. Rank hold SUPN as of Q4 2017.

  • AHL Partners held 27,437 shares of Supernus Pharmaceuticals worth $1.09M as of Q4 2017.
  • AHL Partners sold 90,703 Supernus Pharmaceuticals shares in Q4 2017, an estimated $3.58M.
  • Supernus Pharmaceuticals made up 0.02% of AHL Partners's portfolio in Q4 2017, its #865 holding.
  • AHL Partners first reported a position in Supernus Pharmaceuticals in Q2 2017 and has held it in 3 quarters since.
  • AHL Partners's Supernus Pharmaceuticals position peaked at $4.73M in Q3 2017.
  • 297 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q4 2017.

Based on AHL Partners's 13F filing for Q4 2017, filed 14 Feb 2018.